The fund employs a passive management - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials. more
| Time Frame | SBIO | S&P500 |
|---|---|---|
| 1-Week Return | -6.14% | 1.4% |
| 1-Month Return | -18.62% | 1.17% |
| 3-Month Return | -16.13% | 3.14% |
| 6-Month Return | 1.53% | 17.61% |
| 1-Year Return | 36.09% | 15.37% |
| 3-Year Return | 103.3% | 80.54% |
| 5-Year Return | 21.57% | 78.16% |
| 10-Year Return | 112.17% | 259.41% |
| Stock name | Ticker | Weight |
|---|---|---|
CG oncology Inc.
|
CGON |
3.88%
|
Oruka Therapeutics Inc.
|
ORKA |
3.64%
|
Travere Therapeutics Inc.
|
TVTX |
3.49%
|
Definium Therapeutics Inc.
|
DFTX |
3.27%
|
Dianthus Therapeutics Inc.
|
DNTH |
3.21%
|
VeraDermics Inc.
|
MANE |
3.17%
|
Edgewise Therapeutics Inc.
|
EWTX |
2.92%
|
Relay Therapeutics Inc.
|
RLAY |
2.7%
|
Xenon Pharmaceuticals Inc.
|
XENE |
2.39%
|
Ideaya Biosciences Inc.
|
IDYA |
2.34%
|
Amylyx Pharmaceuticals Inc.
|
AMLX |
2.27%
|
ACADIA Pharmaceuticals Inc.
|
ACAD |
2.23%
|
Tarsus Pharmaceuticals Inc.
|
TARS |
2.08%
|
Denali Therapeutics Inc.
|
DNLI |
2.08%
|
Dyne Therapeutics Inc.
|
DYN |
1.85%
|
MBX Biosciences Inc.
|
MBX |
1.83%
|
Newamsterdam Pharma Co. NV
|
NAMS |
1.8%
|
Zai Lab Ltd.
|
ZLAB |
1.78%
|
Celldex Therapeutics Inc.
|
CLDX |
1.62%
|
Disc Medicine Inc.
|
IRON |
1.61%
|
Immunome Inc.
|
IMNM |
1.54%
|
SELLAS Life Sciences Group Inc.
|
SLS |
1.54%
|
Viridian Therapeutics Inc.
|
VRDN |
1.43%
|
Vera Therapeutics Inc.
|
VERA |
1.43%
|
Mineralys Therapeutics Inc.
|
MLYS |
1.36%
|
BioCryst Pharmaceuticals Inc.
|
BCRX |
1.36%
|
Vericel Corp.
|
VCEL |
1.34%
|
Structure Therapeutics Inc.
|
GPCR |
1.28%
|
Lakefront Biotherapeutics NV
|
LKFT |
1.27%
|
Palvella Therapeutics Inc.
|
PVLA |
1.24%
|
Agios Pharmaceuticals Inc.
|
AGIO |
1.23%
|
Sarepta Therapeutics Inc.
|
SRPT |
1.2%
|
Xencor Inc.
|
XNCR |
1.2%
|
Zenas Biopharma Inc.
|
ZBIO |
1.2%
|
Nuvation Bio Inc.
|
NUVB |
1.17%
|
Generate Biomedicines Inc.
|
GENB |
1.14%
|
Stoke Therapeutics Inc.
|
STOK |
1.07%
|
Compass Pathways PLC
|
CMPS |
1.07%
|
Rapport Therapeutics Inc.
|
RAPP |
1%
|
Immunocore Holdings PLC
|
IMCR |
0.99%
|
Taysha Gene Therapies Inc.
|
TSHA |
0.98%
|
Nektar Therapeutics
|
NKTR |
0.97%
|
Maze Therapeutics Inc.
|
MAZE |
0.95%
|
ArriVent Biopharma Inc.
|
AVBP |
0.91%
|
Kailera Therapeutics Inc.
|
KLRA |
0.88%
|
MannKind Corp.
|
MNKD |
0.79%
|
Tyra Biosciences Inc.
|
TYRA |
0.79%
|
LB Pharmaceuticals Inc.
|
LBRX |
0.78%
|
Bicara Therapeutics Inc.
|
BCAX |
0.76%
|
Immatics NV
|
IMTX |
0.74%
|
Vor BioPharma Inc.
|
VOR |
0.72%
|
MeiraGTx Holdings PLC
|
MGTX |
0.67%
|
Seaport Therapeutics Inc.
|
SPTX |
0.64%
|
Alto Neuroscience Inc.
|
ANRO |
0.63%
|
Kura Oncology Inc.
|
KURA |
0.62%
|
Corvus Pharmaceuticals Inc.
|
CRVS |
0.6%
|
Rigel Pharmaceuticals Inc.
|
RIGL |
0.57%
|
SpyGlass Pharma Inc.
|
SGP |
0.54%
|
Candel Therapeutics Inc.
|
CADL |
0.51%
|
Design Therapeutics Inc.
|
DSGN |
0.5%
|
Geron Corp.
|
GERN |
0.5%
|
4D Molecular Therapeutics Inc.
|
FDMT |
0.49%
|
Wave Life Sciences Inc.
|
WVE |
0.48%
|
Solid Biosciences Inc.
|
SLDB |
0.48%
|
Olema Pharmaceuticals Inc.
|
OLMA |
0.47%
|
Aclaris Therapeutics Inc.
|
ACRS |
0.42%
|
Climb Bio Inc.
|
CLYM |
0.41%
|
Fulgent Genetics Inc.
|
FLGT |
0.38%
|
Oculis Holding AG
|
OCS |
0.35%
|
Altimmune Inc.
|
ALT |
0.34%
|
Delcath Systems Inc.
|
DCTH |
0.34%
|
Allogene Therapeutics Inc.
|
ALLO |
0.33%
|
Neurogene Inc.
|
NGNE |
0.33%
|
Tectonic Therapeutic Inc.
|
TECX |
0.29%
|
Contineum Therapeutics Inc.
|
CTNM |
0.28%
|
AgomAb Therapeutics NV
|
AGMB |
0.27%
|
Eikon Therapeutics Inc.
|
EIKN |
0.26%
|
Zura Bio Ltd.
|
ZURA |
0.25%
|
Rezolute Inc.
|
RZLT |
0.25%
|
Relmada Therapeutics Inc.
|
RLMD |
0.25%
|
Enanta Pharmaceuticals Inc.
|
ENTA |
0.24%
|
Arcturus Therapeutics Holdings Inc.
|
ARCT |
0.24%
|
C4 Therapeutics Inc.
|
CCCC |
0.23%
|
Fulcrum Therapeutics Inc.
|
FULC |
0.18%
|
X4 Pharmaceuticals Inc.
|
XFOR |
0.18%
|
Inhibikase Therapeutics Inc.
|
IKT |
0.18%
|
Upstream Bio Inc.
|
UPB |
0.18%
|
SAB Biotherapeutics Inc.
|
SABS |
0.17%
|
Immuneering Corp.
|
IMRX |
0.17%
|
Evommune Inc.
|
EVMN |
0.16%
|
Akebia Therapeutics Inc.
|
AKBA |
0.15%
|
MacroGenics Inc.
|
MGNX |
0.15%
|
Sionna Therapeutics Inc.
|
SION |
0.14%
|
Bicycle Therapeutics PLC
|
BCYC |
0.11%
|
Anavex Life Sciences Corp.
|
AVXL |
0.11%
|
Protara Therapeutics Inc.
|
TARA |
0.1%
|
NovaBridge Biosciences
|
NBP |
0.1%
|
Compass Therapeutics Inc.
|
CMPX |
0.1%
|
Immunic Inc.
|
IMUX |
0.07%
|
Tenax Therapeutics Inc.
|
TENX |
0.05%
|
Cash Equivalent
|
USD |
0.01%
|
Novo Nordisk A/S
|
Novo.Nordisk.A.S |
0%
|
AstraZeneca PLC
|
AstraZeneca.PLC |
0%
|
Chinook Therapeutics Inc.
|
Chinook.Therapeutics.Inc. |
0%
|
| Sector | Weight |
|---|---|
|
Health care
|
100.00% |
ALPS Medical Breakthroughs ETF (SBIO) share price today is $54.38.
Yes, Indians can buy shares of ALPS Medical Breakthroughs ETF (SBIO) on Vested. To buy SBIO from India, you can open a US Brokerage account by signing up on Vested. The account opening process is completely digital and secure, and takes 3-5 minutes to complete.
Yes, you can purchase fractional shares of ALPS Medical Breakthroughs ETF (SBIO) on Vested. You can start investing in ALPS Medical Breakthroughs ETF (SBIO) with a minimum investment of $1.
The 52-week high price of ALPS Medical Breakthroughs ETF (SBIO) is $70.85. The 52-week low price of ALPS Medical Breakthroughs ETF (SBIO) is $39.52.
The stock symbol (or ticker) of ALPS Medical Breakthroughs ETF is SBIO.
Yes, you can setup SIP in ALPS Medical Breakthroughs ETF shares. Follow the below steps to create the SIP:
Here is the historical performance of SBIO on the Vested app.
The expense ratio of ALPS Medical Breakthroughs ETF (SBIO) is 0.5%.
Link copied
